Zuckerman, Eli
Merck & Co., Inc., Rahway, NJ, USA (United States)
4 papers on CoChat
Most cited papers
- Verified
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 1,277
- Verified
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 220
- Verified
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 127
- Verified
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 75
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free